Digital Mammography with 3D Tomosynthesis

What is a 3D mammogram (tomosynthesis)?

During the examination the machine takes a series of low-dose exposures across an arc and reconstructs them into slices about a millimetre thick. The radiologist reads the breast the way one reads a book — page by page — while a synthesised 2D image preserves the classic overview. For you, the examination feels essentially identical to a standard mammogram: the same positioning, the same brief compression, a few seconds longer per view.

Why 3D beats 2D where it matters

Large screening programmes have shown tomosynthesis finds more invasive cancers than 2D mammography alone and reduces recalls — the anxious return visits for superimposed-tissue shadows. The advantage concentrates exactly where 2D struggles most: dense breasts, where normal fibroglandular tissue is white, cancers are white, and a flat image lets one hide behind the other. Slicing separates them. Density itself matters enough that a good report states your category and what it implies for supplementary imaging.

Dense breasts: the honest conversation

Roughly half of screening-age women have dense breast tissue. Density lowers mammography’s sensitivity — 3D less so than 2D, but the effect remains — and independently raises risk modestly. The honest pathway: know your density from the report; in dense breasts, supplementary breast ultrasound can add detection, and in high-risk profiles breast MRI enters the conversation. No single tool is the whole answer; the combination is chosen with your physician against your risk profile.

The examination: what to expect

Positioning and compression mirror a standard mammogram — compression lasts seconds per view and is firm rather than painful for most women; scheduling after menstruation reduces tenderness. The radiation dose of modern tomosynthesis with synthesised 2D sits in the same low range as digital mammography — a dose regulators accept for population screening precisely because the benefit outweighs it. Results follow as a structured report with your density category and a clear recommendation.

Screening and diagnosis — both jobs

Tomosynthesis serves twice: as a screening examination on the schedule your physician recommends by age and risk, and as a diagnostic tool when something needs a closer look — a lump, discharge, a screening finding. In diagnostic work the slices localise a finding precisely enough to guide the next step, whether targeted ultrasound, MRI or a needle biopsy under imaging guidance. Within Acibadem’s breast health units, that whole pathway — imaging, biopsy, pathology, and tumour-board planning where needed — runs under one roof.

3D mammography at Acibadem

Tomosynthesis operates across the group’s breast imaging practice — with corporate-verified 3D tomosynthesis installations from Istanbul’s breast centres to City Clinic Mladost in Sofia and the Bel Medic centres in Belgrade — read by radiologists working beside the breast health teams. Comparisons with prior mammograms are part of every reading, so bring or send earlier images; they sharpen the answer.

From image to answer: how findings are graded

Every mammogram report speaks one international language: BI-RADS, the category system that turns an image into a decision. Categories 1 and 2 mean normal or definitely benign — routine screening continues. Category 3 means probably benign: a finding with a very low probability of malignancy, watched at a short interval rather than biopsied, which is a designed feature of the system rather than hedging. Categories 4 and 5 mean a biopsy should settle it — and “biopsy” today means an image-guided needle sample under local anaesthesia, not surgery: stereotactic or tomosynthesis-guided for calcifications, ultrasound-guided for masses, with results in days. Category 0 simply means more imaging is needed to decide — the recall that 3D has made rarer. Knowing the code demystifies the letter that arrives after screening: most letters are category 1–2, and even category 4 findings prove benign more often than not. The system’s whole point is that nothing suspicious waits, and nothing innocent gets over-treated.

A screening life: putting the pieces together

Breast screening is a decades-long relationship, and tomosynthesis is its workhorse rather than its entirety. The pattern that serves most women: know your personal risk once — family history, genetics where relevant, density from your first mammogram — then run the schedule your physician sets, on the same platform where possible so comparisons stay sharp. Dense-breast findings may add same-day ultrasound; high-risk profiles may add MRI on an alternating rhythm; symptoms between rounds — a new lump, skin change, discharge — always outrank the calendar and earn a diagnostic visit now, not at the next slot. Within Acibadem’s breast health units, screening, diagnostic work-up, needle biopsy, pathology and — where ever needed — tumour-board planning live on one corridor, so the distance from “the letter” to “the answer” is measured in days.